{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FDC&page=5", "query": { "condition": "FDC", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 144, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FDC&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FDC&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T04:33:57.390Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05747794", "title": "Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Breast Carcinoma" ], "interventions": [ { "name": "eftilagimod alpha", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Immutep S.A.S.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2023-05-22", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-20T04:33:57.390Z", "location_count": 5, "location_summary": "Whittier, California • Washington D.C., District of Columbia • Rock Hill, South Carolina + 1 more", "locations": [ { "city": "Whittier", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Rock Hill", "state": "South Carolina" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05747794" }, { "nct_id": "NCT07619131", "title": "A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolaemia" ], "interventions": [ { "name": "Laroprovstat", "type": "DRUG" }, { "name": "Rosuvastatin 1", "type": "DRUG" }, { "name": "Rosuvastatin 2", "type": "DRUG" }, { "name": "Laroprovstat/Rosuvastatin 1", "type": "DRUG" }, { "name": "Placebo to match rosuvastatin", "type": "DRUG" }, { "name": "Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1", "type": "DRUG" }, { "name": "Laroprovstat/Rosuvastatin 2", "type": "DRUG" }, { "name": "Placebo to match Laroprovstat/Rosuvastatin 2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 600, "start_date": "2026-08-12", "completion_date": "2027-07-30", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-20T04:33:57.390Z", "location_count": 77, "location_summary": "Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 69 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07619131" }, { "nct_id": "NCT02164513", "title": "A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "fluticasone furoate (FF)", "type": "DRUG" }, { "name": "vilanterol (VI)", "type": "DRUG" }, { "name": "umeclidinium bromide (UMEC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 10355, "start_date": "2014-06-30", "completion_date": "2017-07-17", "has_results": true, "last_update_posted_date": "2018-10-10", "last_synced_at": "2026-10-20T04:33:57.390Z", "location_count": 269, "location_summary": "Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 226 more", "locations": [ { "city": "Athens", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Florence", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02164513" }, { "nct_id": "NCT07314346", "title": "Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer Study" ], "interventions": [ { "name": "Buprenorphine/Naloxone + BEM/RZR", "type": "DRUG" }, { "name": "Methadone +BEM/RZR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Atea Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 32, "start_date": "2025-01-07", "completion_date": "2026-08", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-20T04:33:57.390Z", "location_count": 3, "location_summary": "Hollywood, Florida • Overland Park, Kansas • Marlton, New Jersey", "locations": [ { "city": "Hollywood", "state": "Florida" }, { "city": "Overland Park", "state": "Kansas" }, { "city": "Marlton", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07314346" }, { "nct_id": "NCT03642067", "title": "Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Microsatellite Stable (MSS) Colorectal Adenocarcinomas", "Colorectal Adenocarcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Relatlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2019-02-12", "completion_date": "2024-09-18", "has_results": true, "last_update_posted_date": "2025-06-15", "last_synced_at": "2026-10-20T04:33:57.390Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03642067" }, { "nct_id": "NCT02741557", "title": "Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "DTG", "type": "DRUG" }, { "name": "RPV", "type": "DRUG" }, { "name": "DTG/RPV FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 118, "start_date": "2016-05-11", "completion_date": "2016-10-24", "has_results": false, "last_update_posted_date": "2019-07-15", "last_synced_at": "2026-10-20T04:33:57.390Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02741557" }, { "nct_id": "NCT02993237", "title": "Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1" ], "interventions": [ { "name": "DRV/COBI FDC placebo tablet", "type": "DRUG" }, { "name": "D/C/F/TAF FDC placebo tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 27, "start_date": "2017-01-23", "completion_date": "2017-05-25", "has_results": false, "last_update_posted_date": "2019-05-13", "last_synced_at": "2026-10-20T04:33:57.390Z", "location_count": 4, "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Memphis, Tennessee + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02993237" }, { "nct_id": "NCT02639247", "title": "Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "SOF/VEL/VOX", "type": "DRUG" }, { "name": "SOF/VEL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 333, "start_date": "2015-12-23", "completion_date": "2017-01-18", "has_results": true, "last_update_posted_date": "2019-03-05", "last_synced_at": "2026-10-20T04:33:57.390Z", "location_count": 43, "location_summary": "Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Rialto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02639247" }, { "nct_id": "NCT02184585", "title": "Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Hyperplasia" ], "interventions": [ { "name": "Treatment sequence A", "type": "DRUG" }, { "name": "Treatment sequence B", "type": "DRUG" }, { "name": "Treatment sequence C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "18 Years to 65 Years · Male only" }, "enrollment_count": 84, "start_date": "2014-07-10", "completion_date": "2015-02-23", "has_results": false, "last_update_posted_date": "2018-06-19", "last_synced_at": "2026-10-20T04:33:57.390Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02184585" }, { "nct_id": "NCT00860262", "title": "Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "amlodipine", "type": "DRUG" }, { "name": "telmisartan", "type": "DRUG" }, { "name": "telmisartan and amlodipine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 858, "start_date": "2009-03", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-05-20", "last_synced_at": "2026-10-20T04:33:57.390Z", "location_count": 30, "location_summary": "Buena Park, California • Long Beach, California • Roseville, California + 26 more", "locations": [ { "city": "Buena Park", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Tustin", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00860262" } ] }